Roivant Sciences Ltd.

1 day ago · defenseworld.net

Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) Director Melissa Epperly sold 4,938 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $39.74, for a total value of $196,236.12. Following the completion of the transaction, the director owned 9,900 shares in the company, valued

8 days ago · seekingalpha.com

LISRAYA's recent approval gives ROIV a nice commercial foundation, while additional indications could turn brepocitinib into a broader immunology franchise. ROIV's pulmonary asset with mosliciguat is also promising. This candidate may be helpful for vascular resistance and walking distance improvements. I believe mosliciguat could over time become a valuable pulmonary franchise, but we still need to see how its subsequent Phase 3 plays out.

11 days ago · seekingalpha.com

Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

12 days ago · seekingalpha.com

Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

13 days ago · seekingalpha.com

Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

13 days ago · seekingalpha.com

Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript

13 days ago · benzinga.com

Pulmovant, a clinical-stage biotech and Roivant (NASDAQ:ROIV) company, on Tuesday shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD).

13 days ago · reuters.com

Roivant said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with ​high blood pressure associated with a type of lung ‌disease, sending shares up about 20% in premarket trading.

13 days ago · globenewswire.com

WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. The results will be presented today at the European Respiratory Society (ERS) International Congress 2026.

13 days ago · globenewswire.com

BASEL, Switzerland and LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. The results will be presented today at the European Respiratory Society (ERS) International Congress 2026.